Bisphosphonates are an important option for the prevention offractures in postmenopausal women. However, the complex instructionsfor the administration of oral bisphosphonates are inconvenientor unsuitable for many patients, and adherence to long-termtherapy is poor.1 The introduction of oral regimens for administrationonce weekly and, recently, once monthly has been associatedwith improved tolerability for patients, although adherenceremains suboptimal.2 The demonstration that once-yearly intravenousinfusions of zoledronic acid produced a sustained reductionin bone turnover and increased bone mineral density raised theprospect that even less frequent administration and the hopeof better adherence might be realized.3. . . [Full Text of this Article]
Source Information
From the Department of Medicine, University of Cambridge School of Clinical Medicine and Addenbrooke's National Health Service Trust, Cambridge, United Kingdom.
This article has been cited by other articles:
de Nijs, R. N.J., Westgeest, A. A.A., Poole, K. E.S., Kaptoge, S., Reeve, J., Karam, R., Camm, J., McClung, M., Najib, M. A., Aziz, I., Chang, J. T., Black, D., Eriksen, E., Sellmeyer, D., Compston, J.
(2007). Yearly zoledronic acid in postmenopausal osteoporosis.. NEJM
357: 711-712
[Full Text]
(2007). Bisphosphonate Therapy . . . Once a Year. JWatch Women's Health
2007: 4-4
[Full Text]
Previous
